Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): Genetic basis of susceptibility to infection and response to antiviral treatment

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages 1237-1245

  Riva, E ^a   Scagnolari, C ^b   Turriziani, O ^b   Antonelli, G ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HCV infection; Host genetics; Interferon 3; Interferon 4; Single nucleotide polymorphisms

Indexed keywords

BOCEPREVIR; DACLATASVIR; DANOPREVIR; INTERFERON; INTERFERON LAMBDA4; INTERLEUKIN 28B; LEDIPASVIR; MERICITABINE; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; DISEASE COURSE; ETHNICITY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IL 28B GENE; INFECTION SENSITIVITY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS CELL INTERACTION; GENETICS; IMMUNOLOGY; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; INTERLEUKINS; TREATMENT OUTCOME;

EID: 84920396193     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12797     Document Type: Review

References (76)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
2. Antonelli G, Riva E, Maggi F, Vatteroni ML, Simeoni E. Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon-alpha. J Infect Dis 1999; 180: 1411-1412.
3. Antonelli G, Simeoni E, Turriziani O et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999; 19: 243-251.
4. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039.
5. Heim MH. Innate immunity and HCV. J Hepatol 2013; 58: 564-574.
6. Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010; 2010: 703602.
7. Scagnolari C, Bellomi F, Trombetti S et al. Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol 2007; 147: 270-276.
8. Naito M, Matsu A, Inao M et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 381-388.
9. Tsukada H, Ochi H, Maekawa T et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009; 136: 1796-1805.
10. Matsuyama N, Mishiro S, Sugimoto M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003; 25: 221-225.
11. Knapp S, Yee LJ, Frodsham AJ et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4: 411-419.
12. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
13. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
14. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284: 20869-20875.
15. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
16. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
17. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
18. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
19. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-1269.
20. McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
21. Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
22. Riva E, Scagnolari C, Monteleone K et al. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. J Viral Hepat 2012; 19: 650-653.
23. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
24. Tillmann HL, Thompson AJ, Patel K et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592.
25. Abe H, Ochi H, Maekawa T et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-443.
26. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 406-417.
27. Li JH, Lao XQ, Tillmann HL, Rowell J et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-1911.
28. Tillmann HL, Patel K, Muir AJ et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011; 55: 1195-1200.
29. Lagging M, Askarieh G, Negro F et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
30. Beinhardt S, Aberle JH, Strasser M et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012; 142: 78-85.
31. Bitetto D, Fattovich G, Fabris C et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118-1126.
32. Suppiah V, Gaudieri S, Armstrong NJ et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
33. Miki D, Ochi H, Takahashi A, Hayes CN et al. HLA-DQB1**03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. PLoS ONE 2013; 8: e84226.
34. Jiménez-Sousa MA, Berenguer J, Rallón N et al. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. J Viral Hepat 2013; 20: 358-366.
35. Scherzer TM, Stättermayer AF, Strasser M et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology 2011; 54: 1518-1526.
36. Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
37. Kawaoka T, Hayes CN, Ohishi W et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-414.
38. Moghaddam A, Melum E, Reinton N et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
39. Scherzer TM, Hofer H, Staettermayer AF et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-871.
40. Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 2013; 19: 8924-8928.
41. Gupta AC, Trehanpati N, Sukriti S et al. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3. J Med Virol 2014; 86: 707-712.
42. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
43. Russell CD, Griffiths SJ, Haas J. Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol 2014; 33: 60-63.
44. Smith KR, Suppiah V, O'Connor K et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011; 3: 57-70.
45. Honda M, Nakamura M, Tateno M et al. Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C. J Hepatol 2010; 53: 817-826.
46. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
47. Abe H, Hayes CN, Ochi H et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094-1101.
48. Asselah T, Bieche I, Narguet S et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-524.
49. Younossi ZM, Baranova A, Afendy A et al. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 2009; 49: 763-774.
50. Giannelli G, Guadagnino G, Dentico P, Antonelli G, Antonaci S. MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004; 24: 659-663.
51. Abe H, Hayes CN, Ochi H et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83: 1597-1607.
52. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14: 36-49.
53. Shebl FM, Maeder D, Shao Y, Prokunina-Olsson L, Schadt EE, O'Brien TR. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 2010; 139: 1422-1424.
54. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
55. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
56. Gaetano JN. Benefit?risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014; 6: 37-45.
57. Tatsuo K, Shingo N, Shuang W, Osamu Y. New treatments for genotype 1 chronic hepatitis C ? focus on simeprevir. Ther Clin Risk Manag 2014; 10: 387-394.
58. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 14: 1669-1679.
59. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369: 678-679.
60. Chu TW, Kulkarni R, Gane EJ et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790-795.
61. Zeuzem S, Soriano V, Asselah T et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639.
62. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370: 1560-1561.
63. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
64. Hamming OJ, Terczyńska-Dyla E, Vieyres G et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32: 3055-3065.
65. Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA. IFNλ4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS 2014; 28: 133-136.
66. Stättermayer AF, Strassl R, Maieron A et al. Polymorphisms of interferon-λ4 and IL28B-effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014; 39: 104-111.
67. Meissner EG, Bon D, Prokunina-Olsson L et al. IFNλ4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209: 1700-1704.
68. Bibert S, Roger T, Calandra T et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116.
69. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-λ4 (IFNλ4) transcript expression in human liver tissue samples. PLoS ONE 2013; 8: e84026.
70. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
71. García-Martín E, Agúndez JA, Maestro ML et al. Influence of Vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. PLoS ONE 2013; 8: e74764.
72. Suppiah V, Gaudieri S, Armstrong NJ et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
73. De Rueda PM, López-Nevot MÁ, Sáenz-López P et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011; 106: 1246-1254.
74. Neukam K, Almeida C, Caruz A et al. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. Antimicrob Chemother 2013; 68: 915-921.
75. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010; 85: 190-200.
76. Martin MA, Kroetz DL. Abacavir pharmacogenetics-from initial reports to standard of care. Pharmacotherapy 2013; 33: 765-775.